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Abstract
IL6 is a multifunctional cytokine that drives terminal B cell differentiation and secretion of
immunoglobulins. IL6 also cooperates with IL21 to promote differentiation of CD4+ T follicu-
lar helper cells (TFH). Elevated serum levels of IL6 correlate with disease flares in patients
with systemic lupus erythematosus (SLE). We previously reported that IL21 produced by
TFH plays a critical role in the development of the SLE-like disease of BXSB.Yaamice. To
examine the possible contributions of IL6 to disease, we compared disease parameters in
IL6-deficient and IL6-competent BXSB.Yaamice. We report that survival of IL6-deficient
BXSB.Yaamice was significantly prolonged in association with significant reductions in a
variety of autoimmune manifestations. Moreover, B cells stimulated by co-engagement of
TLR7 and B cell receptor (BCR) produced high levels of IL6 that was further augmented by
stimulation with Type I interferon (IFN1). Importantly, the frequencies of TFH and serum lev-
els of IL21 were significantly reduced in IL6-deficient mice. These findings suggest that
high-level production of IL6 by B cells induced by integrated signaling from the IFN1 recep-
tor, TLR7 and BCR promotes the differentiation of IL21-secreting TFH in a signaling
sequence that drives the lethal autoimmune disease of BXSB.Yaamice.
Introduction
Systemic lupus erythematosus (SLE) is a multigenic autoimmune disorder characterized by the
formation and accumulation of immune complexes that cause tissue damage. In humans, the
disease is more prevalent in females than males. Approximately 40 genes have been identified as
genetic susceptibility loci for the disease, revealing the complexity of inheritance that underlies
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the disorder [1]. Cardinal features of SLE include chronic B cell activation accompanied by the
presence of antibodies to a range of self-antigens including anti-nuclear and anti-double
stranded DNA antibodies (ANA and dsDNA, respectively). Studies of genetically-programmed
mouse models of SLE have advanced our understandings of the mechanisms involved in disease
pathogenesis. BXSB.Yaamice develop a severe humoral autoimmune disease that shares many
features with human SLE. Male mice of this strain carry the Y-linked autoimmune accelerator
(Yaa) mutation due to the chromosomal translocation of a portion of the X to the Y chromo-
some resulting in a duplication of a number of genes including Tlr7 [2, 3]. This results in male
mice carrying two functional copies of Tlr7 in contrast to BXSB females that express only one
functional copy due to X inactivation and BXSB males carrying a wild-type Y-chromosome.
The doubling of Tlr7 expression in BXSB.Yaamales is sufficient to greatly accelerate the mild,
late onset SLE-like autoimmune disease observed in females after 1 year of age to a much more
acute disease with deaths averaging 6 months of age [4, 5]. TLR7 binds single stranded RNA
(ssRNA) leading to activation of a signaling cascade that results in the production of Type I IFN
(IFN1) and inflammatory cytokines including TNFα and IL6 [6–8]. In addition, disease flares in
human SLE are often associated with heightened expression of IL6 as well as IFN1 that height-
ens B cell sensitivity to various stimuli.
Previous studies centering on CD4+ T follicular helper cells (TFH) have identified several
additional major determinants of disease. First, IL21, a γc cytokine produced primarily by TFH
and extrafollicular TFH in BXSB.Yaamice, is an absolute requirement for disease [9, 10]. This
conclusion is based on studies showing that mice deficient in expression of the IL21 receptor
(IL21R) exhibited no signs of disease, thereby identifying IL21 as a non-redundant cytokine
central to disease initiation and progression [9]. Second, disease progression in BXSB.Yaamice
is restricted by an axis governed by CD8+ T suppressor (Ts) cells and NK cells. These cell popu-
lations are also dependent on IL21 as shown by studies demonstrating that the appearance of
multiple signs of disease and as well as mortality are greatly accelerated in BXSB.Yaamice
bearing null alleles of both Cd8 and Il15 [10] and that the regulatory activity of CD8 T cells
depends on IL21 signaling [11]. Thus, the development of TFH that secrete high levels of IL21
is a central component of the BXSB.Yaa disease.
The mechanisms that drive the expansion of TFH and heightened expression of IL21 by TFH
in BXSB.Yaamice have not been defined. IL6 is an attractive candidate as a promotor of these
phenotypes and, more generally, of the pathogenesis of SLE. A number of studies in humans
and mice have identified roles for IL6 in conjunction with IL21 in TFH differentiation [12–16].
Recently, it was shown that activation of STAT1 by IL6 is critical to the transcriptional activa-
tion of Bcl6 and Cxcr5 in the early processes of TFH differentiation with IL21 appearing to con-
tribute to the later phases of the differentiation program [17]. In addition, the established roles
of IL6 in late B cell development suggest it may contribute to the massive accumulations of
extrafollicular plasmablasts and plasma cells identified in lymphoid tissues of BXSB.Yaamice
[10]. Possible contributions of IL6 to disease in human SLE and in mouse models of lupus were
first suggested by the identification of elevated levels of IL6 levels in sera of patients with SLE
[18–22]. Mouse models of SLE, such as MRL.Faslpr have been found to have increased serum
levels of IL6 that progress with age [18, 19]. In addition, IL6 was shown to increase the B cell-
mediated autoantibody production in NZB/W F1 mice [23]. Finally, IL6 has been identified as
one of the major genetic risk factors for human SLE as determined by genome-wide association
studies (GWAS) [24].
The present study was aimed at determining whether IL6 plays an important role in the
development of the SLE-like disease of BXSB.Yaamice. We observed that BXSB.Yaamice had
elevated serum levels of IL6 that correlated with the appearance and progression of disease
findings, including the expansion of TFH. We also found that B cells, which exhibited an
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activated phenotype, were a prominent source of IL6. Remarkably, the survival of BXSB.Yaa
mice homozygous for a null allele of Il6 (Il6-/-) was greatly prolonged over that of WT mice,
and major signs of disease in younger mice were markedly attenuated.
Materials and Methods
Mice
BXSB.Yaa/MpJ (JR740) mice from the Jackson Laboratory were housed at a NIAID or Jackson
Laboratory animal facility. Male and female mice of this strain are designated as BXSB.Yaa and
BXSB respectively. IL6-deficient BXSB.Yaamice (BXSB.YaaIl6-/- or BXSB.Il6+/-) were gener-
ated by crossing the IL6 knockout construct from B6.129S2-Il6-/-(B6.129S2-Il6tm1Kopf/J,
JR2650) with BXSB.Yaa/MpJmice for 11 generations. Mice were genotyped for the Il6 knock-
out allele using oligonucleotide primer sequences TCCATCCAGTTGCCTTCTTGG (common),
TTCTCATTTCCACGATTTCCCA (wild type reverse) and CGGAGAACCTGCGTGCAAT (mutant
reverse). In some experiments, BXSB.B6Y consomic controls (BXSB.B6-Yaa+/MobJDcr) were
used in which the Y chromosome from C57BL/6J was transferred onto BXSB, thereby replacing
the BXSB Yaa chromosome. All mice used in the study were maintained under specific patho-
gen free conditions and were fed with standard feed and water ad libitum.
Ethics Statement
Animal Ethics Committees of NIAID, NIH and the Jackson Laboratory approved all experi-
ments. The experiment procedures were in accordance with the guidelines of ASP LIG-16
approved by the Institutional Animal Care and Use Committee (IACUC) of NIAID and
#01022 approved by The Jackson Laboratory Institutional Animal Care and Use Committee.
BXSB.Yaamales and control animals were monitored daily for the development of enlarged
lymph nodes. The animals were also monitored for splenomegaly by occasional palpitations.
Once BXSB.Yaamice were diagnosed with visible signs of disease, they were sacrificed immedi-
ately by CO2 asphyxiation along with age matched BXSB female controls.
Cell isolation and culture
Single cell suspensions were prepared from spleen, bone marrow (BM), lymph nodes and peri-
toneal washouts. Specific cell populations were isolated using standard protocols. CD43- B cells
were isolated by CD43 (Ly-48) microbeads (Miltenyi) using the negative selection method.
Splenic dendritic cells (DCs) were isolated using a mouse dendritic cell enrichment set (BD Bio-
sciences) using the manufacturer’s protocol. BM-derived dendritic cells (BM-DCs) were gener-
ated by culturing BM cells (106/ml) with GM-CSF (40ng/ml) (Peprotech) and IL4 (20ng/ml)
(Peprotech). Media were replenished with fresh cytokine-containing media on days 3, 7 and 9
of culture. Cells were harvested on day 11 and purity was determined by flow cytometry to be
94–95%. Peritoneal macrophages were obtained by adhering peritoneal washout cells to tissue
culture plates for 4–5 hours. The non-adherent fraction was removed by repeated washing with
sterile ice cold PBS and adherent cells were used for experiments. CD115+ monocytes were iso-
lated by positive selection of CD115+ cells using a CD115 microbead kit (Miltenyi) following
the manufacturer’s protocol. FcR blocking was performed using the 2.4G2 monoclonal antibody
(BD Biosciences) as necessary.
Specific cell populations were cultured in the presence of the TLR7 agonist, Imiquimod
(R837; Invivogen), for 24–48 hours in complete RPMI-1640 medium (Quality Biological)
(RPMI-1640 medium supplemented with 10% FBS (Quality Biological, Lot#205C13), sodium
pyruvate, non-essential amino acids, penicillin, streptomycin (all from Quality Biological) and
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2-mercaptoethanol (GIBCO)). Cells or culture supernatants were harvested for further studies.
In some experiments, B cells were cultured in the presence of anti-BCR antibody (2μg/ml;
F(ab’)2 fragment goat anti-mouse IgM, μ chain specific; Jackson Immunoresearch), IFNα or
IFNβ (20ng/ml; PBL Biomedical Laboratories).
Flow cytometry (FACS)
Standard multiparameter FACS analyses were performed using a BD LSRII instrument and anti-
bodies listed in S1 Table. Data were collected using FACS Diva software and analyzed using
FlowJo software (Tree Star). Doublet discrimination was performed and viable cells were gated
using the propidium iodide exclusion method. B cell activation was assessed using surface
expression of CD40, MHCII, ICOSL and CD86. Total splenic B cells were defined as B220+IgM+
cells and expression levels of IL21R and FAS were measured in terms of mean fluorescence inten-
sity (MFI). Marginal zone B cells were defined as CD19+IgM+B220+CD5-CD23-CD21+, whereas
follicular B cells were defined as CD19+IgM+B220+CD5-CD23hiCD21lo/-. Germinal center (GC)




(a) IL6 and IL21 ELISA. Culture supernatants (neat) or serum (1:20) were added to 96-well
ELISA plates (Costar) coated with either purified anti-mouse-IL6 antibody (BD Biosciences) or
anti-mouse IL21 antibody (Peprotech). IL6 or IL21 were captured by secondary biotinylated
anti-mouse IL6 antibody (BD Biosciences) or anti-mouse IL21 antibody (Peprotech) followed
by streptavidin-HRP/TMB (Sigma/Invitrogen) for colorimetric estimation. Washing with
PBS-Tween-20 (0.5%) was followed at each step. Results were expressed as ng/ml of secreted
IL6 or IL21 using two-fold serial dilutions of recombinant murine IL6 (BD Biosciences) or
IL21 (Peprotech) as standards.
(b) Antibody isotype ELISA. Unlabeled purified anti-mouse IgG2b (BD Biosciences) and
IgG2c (eBioscience) antibodies were coated on 96-well ELISA plates (Costar) in carbonate-
bicarbonate buffer (pH = 9.6) overnight at 4°C. Plates were blocked with 2% IgG-free BSA
(Jackson ImmunoResearch) for 2 hours at RT and serial dilutions of serum were added. Bound
immunoglobulin isotypes were detected using biotin-labeled antibodies to IgG2b (BD Biosci-
ences) and IgG2c (eBioscience) and color development was detected by streptavidin-HRP
(Sigma) followed by TMB (Invitrogen). Reactions were stopped using 1N HCl and the OD was
read at 450nm. At each step, plates were washed with PBS-Tween-20 (0.5%).
(c) Anti-nuclear antibody (ANA) or anti-dsDNA antibody (anti-DNA) ELISA. ANA and
anti-dsDNA estimation was done using a mouse anti-nuclear Ab Total Ig kit and mouse anti-
dsDNA Ab Total Ig kit (Alpha Diagnostics) following the manufacturer’s instructions. We
used serum dilutions (1:100) on plates pre-coated with extractable nuclear antigens (ENA) for
ANA quantitation (Alpha Diagnostics) or purified dsDNA (Alpha Diagnostics) for anti-
dsDNA quantitation. Bound total Ig (IgG+IgM+IgA) was detected by HRP-labeled anti-mouse
IgG+IgM+IgA (H+L) detection antibody (Alpha diagnostics) and colorimetric estimation was
done using TMB substrate. Stop solution was added to terminate the reaction and color devel-
opment was read at 450nm. All components in the assay were part of the specific kit used.
Cell proliferation assay
Negatively selected purified B cells were cultured in appropriate conditions in 96-well U-bot-
tom plates (Costar) for 24h. 3H-thymidine (0.5 μCi/ well; Perkin Elmer) was added to the cul-
tures and incubated for a further 16h. The cells were then harvested onto glass fiber filter mats
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(Perkin Elmer) using a Tomtec Harvester. Proliferation was measured as 3H- thymidine incor-
poration using a Perkin Elmer β-scintillation counter. Results were expressed as counts per
minute (CPM).
Statistical analysis
All values in the figures are expressed as mean ± SEM of n observations (where n is indicated
in the figure legends). Relevant data sets were compared by one or two way ANOVA, as
deemed appropriate. All data were analyzed using the statistical tools of GraphPad Prism
Software.
Results
BXSB.Yaamice have increased serum levels of IL6 that correlate with
humoral disease manifestations
To study possible contributions of IL6 to the BXSB.Yaa disease, we first compared levels of IL6
in sera from male BXSB.Yaa to levels for female BXSB mice, which develop a mild form of
autoimmunity when older than 1 year [4, 5]. This comparison eliminated contributions of
non-sex chromosome-linked lupus susceptibility genes while emphasizing potential effects of
the Yaa-determined Tlr7 duplication. The results demonstrated that IL6 levels were signifi-
cantly higher in sera of male Yaa compared to female mice, even at 1 month of age (Fig 1A).
Levels peaked in sera from 3–4.5 month old male mice, the age at which disease symptoms
start appearing, but then dropped in older mice. These age-related changes in serum IL6 levels
correlated well with changes in serum levels of ANA and anti-dsDNA antibodies that were
found at higher levels in male than female BXSB mice, again peaking at 3–4.5 months of age
(Fig 1B).
The fact that IL6 is known to augment plasma cell differentiation and immunoglobulin
secretion led us to determine if age-related changes in IL6 expression would correlate with
changes in serum immunoglobulin levels. Analyses of serum IgG2b showed that levels in male
mice increased dramatically between 0.7–1.5 and 1.5–3 months of age and remained equally
high thereafter (Fig 1C). Serum IgG2b levels of female mice also increased with age but were
always substantially lower than for male BXSB.Yaamice at each time point examined. These
same patterns and relationships between sexes were also seen in analyses of serum IgG2c levels
(Fig 1C). From these findings, we concluded that IL6 secretion correlates with the humoral
progression of disease in BXSB.Yaamice.
B cells are prominent producers of IL6
Previous studies in mice showed that B cells secrete IL6 in response to stimulation with TLR7
ligands [6, 25, 26]. In addition, it was shown that lymphoblastoid B cells isolated from lupus
patients produced increased levels of IL6 [27]. To determine whether B cells from different
hematopoietic compartments varied in their ability to produce IL6, we compared levels of IL6
secretion in culture supernatants of CD43- B cells purified from spleen, BM and peritoneal
lavage from male and female BXSB mice. The cells were cultured for 24 hours with or without
the TLR7 agonist, Imiquimod (R837). We found that B cells from BXSB.Yaamice, regardless
of source, secreted significantly higher levels of IL6 than cells from BXSB females when stimu-
lated with R837 (Fig 2A). In addition, the levels of IL6 secreted by unstimulated or R837-stimu-
lated peritoneal B cells were strikingly higher than those secreted by comparable populations of
splenic or BM B cells (note differences in scale). It is known that IL6 is also produced by other
APCs such as conventional splenic dendritic cells (cDCs), bone marrow derived dendritic cells
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Fig 1. IL6 levels correlate with disease manifestations in BXSB.Yaamice. Sera from BXSB.Yaa and
BXSBmice of different ages were collected and tested for the levels of (A) IL6 (B) anti-nuclear antibodies
(ANA) and anti-dsDNA antibodies, and (C) immunoglobulin isotypes (IgG2b and IgG2c); n = 4–20 mice per
age group. Each dot represents one mouse. Horizontal bars represent mean ±SEM. p values are calculated
by one-way ANOVA with Tukey’s multiple comparison tests. * p<0.05, ** p<0.01, ***p<0.0001.
doi:10.1371/journal.pone.0153059.g001
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(BM DCs), peritoneal resident macrophages and CD115+ monocytes. We next compared the
levels of IL6 secreted by these cell subsets isolated from BXSB.Yaa and BXSB mice when stimu-
lated with R837 in vitro. We found that IL6 levels secreted by each stimulated population were
significantly higher in BXSB.Yaa compared with female BXSB control mice; however, these
levels were markedly lower than those produced by any of the B cell populations studied (Fig
2B). This led us to conclude that IL6 secreted primarily by B cells in response to enhanced
Fig 2. B cells from BXSB.Yaamice are potent producers of IL6. (A) CD43- B cells were purified from spleen, BM and peritoneal lavage of 4–5 month old
BXSB.Yaa and BXSBmice and stimulated with graded concentrations of Imiquimod (R837). (B) Dendritic cells enriched from spleen (splenic DCs) or
differentiated from BM precursors (GMCSF (40ng/ml) and IL4 (20ng/ml) for 9 d with media changed every third day), peritoneal macrophages and CD115+
monocytes from spleens of BXSB.Yaa and BXSBmice were stimulated with R837 (50ng/ml) in vitro. Supernatants were collected after 24 hours and IL6
levels were quantified using a standard sandwich ELISA. Data expressed as mean ± SEM of triplicate wells are representative of 4–6 independent
experiments. p values are determined by two-way ANOVA. * p<0.05, ** p<0.01, ***p<0.0001.
doi:10.1371/journal.pone.0153059.g002
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TLR7 expression as the result of Yaa is likely to be an important contributor to development of
SLE-like disease in BXSB.Yaamice.
BCR and TLR7 signaling pathways cooperate to induce IL6 secretion by
B cells
The understanding that B cells are the primary producers of IL6 in BXSB.Yaamice prompted
us to determine whether their B cells are spontaneously activated. We found that the basal
expression levels of activation markers for purified splenic B cells cultured in medium alone
tended to be higher for cells from Yaamales compared with those from female BXSB mice, but
reaching significance only for expression of MHCII (Fig 3A). These differences were greatly
magnified after stimulation with R837 (Fig 3A). From this, we concluded that B cells from
BXSB.Yaamice are activated in the absence of overt stimulation and were substantially more
responsive to activation by ligation of TLR7.
Spontaneous activation of BXSB.Yaa cells may be attributed to the additional copy of Tlr7
that leads to B cell-mediated disease progression. Since TLR7 also promotes the proliferation,
migration and terminal differentiation of murine B cells [28, 29], we further compared the pro-
liferative responses of purified splenic B cells from male Yaa and female BXSB mice to R837
stimulation in vitro. B cells from both BXSB.Yaa and BXSB mice proliferated in a dose-depen-
dent manner in response to TLR7 ligation, but the proliferative responses of B cells from males
were always higher than those from cells from female mice (Fig 3B).
Previous studies have shown that co-stimulation through the BCR and TLR synergizes in
activating B cells and that these activated B cells secrete elevated levels of IL6 [26, 29, 30]. To
determine if B cell activation in BXSB.Yaamice is a consequence of cooperative BCR and TLR
signaling, we stimulated purified splenic B cells from male and female BXSB mice with R837 or
the F(ab’)2 fragment of anti-IgM antibody (BCR), either alone or in combination. Supernatants
of the cultures were assayed for IL6 levels (Fig 3C) and the cells were also assessed for prolifera-
tion (Fig 3D). We found that combined stimulation through TLR7 and the BCR synergistically
augmented IL6 secretion by male and female B cells (Fig 3C). In addition, co-stimulation also
enhanced the proliferative responses of both male and female B cells to these stimuli with the
responses of male cells being significantly greater (Fig 3D). Collectively, these results indicated
that B cells from BXSB.Yaamice have a spontaneously activated phenotype, which is enhanced
by co-engagement of the BCR and TLR7, a combination that also induced enhanced IL6 pro-
duction and proliferation.
IFN1 enhances B cell activation driven by co-ligation of TLR7 and the
BCR
Previous studies showed that IFN1 sensitizes B cells to activation by a number of stimuli [31–
33]. In addition, an “IFN signature”, marked by heightened expression of a series of IFN-
stimulated genes, is associated with flares in human SLE [34–36]. We recently found that
purified B cells from T cell-deficient BXSB.Yaamice as young as 4 weeks of age have a lupus-
like “IFN signature” that develops in the absence of IL21. This signature is induced by expres-
sion of IFN1 by plasmacytoid DC (pDC) via a signaling pathway that is at least partially
dependent on TLR7 (manuscript in preparation). To determine if IFN1 would affect the
responsiveness of B cells from BXSB.Yaamice, we cultured purified splenic B cells from both
male and female BXSB mice in the presence or absence of R837, IFNα and IFNβ. We found
that stimulation of B cells with IFN1 in the presence of a TLR7 ligand significantly enhanced
B cell production of IL6 with male cells being significantly more responsive than female
BXSB cells (Fig 3E). Moreover, additional stimulation through the BCR further stimulated
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Fig 3. BXSB.Yaa B cells exhibit an activated phenotype. (A) Purified CD43- B cells from 4–5 month old
BXSB.Yaa and BXSBmice were stimulated with R837 (50ng/ml) for 24 hours and stained for surface
expression of the activation markers—CD40, MHCII, ICOSL and CD86. Data are expressed as mean ± SEM
of mean fluorescence intensity (MFI) and are pooled from 4–5 independent experiments. (B) Purified CD43- B
cells from 4–5 month old BXSB.Yaa and BXSBmice were stimulated with graded doses of R837 for 24 hours.
3H thymidine (0.5μCi/well) was added and its incorporation was determined after 16 hours by liquid
scintillation counting. Proliferation was determined as counts per minute (CPM). (C-D) CD43- B cells were
stimulated with R837 (50ng/ml) in the presence and absence of anti-BCR antibody. IL6 secretion (C) and B
cell proliferation (D) were determined as described earlier. (E) Purified B cells from 4–5 month old BXSB.Yaa
and BXSBmice were cultured in the presence or absence of R837 (50ng/ml); IFNα and IFNβ (40U/ml), either
alone or in combination, for 24h. Supernatants were collected and quantified for IL6 levels by standard
sandwich ELISA. All data (B-E) are expressed as mean ± SEM of triplicate wells and are representative of
2–3 independent experiments. P values are determined by two-way ANOVA. * p<0.05, ** p<0.01,
***p<0.0001.
doi:10.1371/journal.pone.0153059.g003
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IL6 secretion, indicating that signaling through the IFNAR, TLR7 and the BCR have a coop-
erative effect on IL6 production in BXSB.Yaamice (S1 Fig). From this, we conclude that
stimulation of B cells by both innate (IFN1, TLR7) and adaptive (BCR) signals collectively
enhance IL6 secretion in BXSB.Yaamice.
Abrogating IL6 signaling delays disease in BXSB.Yaamice
To directly assess the importance of IL6 to the SLE-like disease of BXSB.Yaamice, we gener-
ated BXSB.Yaamice homozygous for a null allele of Il6 (BXSB.Yaa.Il6-/-) and studied them for
disease development. First, we compared autoantibody levels in sera from 6–10 month old
BXSB.Yaa.Il6-/-, BXSB.Yaa, and BXSB.B6Y consomic controls carrying a B6 Y chromosome as
well as BXSB.Il6-/- females. We found that ANA levels in sera of IL6-deficient BXSB.Yaamice
were significantly lower than those of BXSB.Yaamice and that they were comparable to those
of female BXSB mice and BXSB.B6Y consomic controls. (Fig 4A). This observation suggested
that IL6 signaling is a major contributor to the development of autoantibodies. To further
address this issue, we compared the survival and disease characteristics of BXSB.Yaa.Il6-/-,
BXSB.Yaa.Il6+/- and BXSB.Yaamice. We found that the survival of BXSB.Yaa.Il6-/- mice was
significantly prolonged compared to that of BXSB.Yaa and BXSB.Yaa.Il6+/- mice (Fig 4B). Fur-
ther studies demonstrated that spleen weights (Fig 4C) and serum levels of IgG2b and IgG1
(Fig 4D) were significantly lower in BXSB.Yaa.Il6-/- than BXSB.Yaa.Il6+/- mice. In addition,
serum levels of anti-dsDNA antibodies were significantly lower in sera of BXSB.Yaa.Il6-/- than
BXSB.Yaamice and were comparable to levels in sera of BXSB.B6Y consomic controls and nor-
mal B6 mice (Fig 4E).
To determine if the cellular effects of IL6 deficiency can be detected in young mice, we first
characterized cells in the blood of 6 week old BXSB.Yaa.Il6-/- and BXSB.Yaa.Il6+/- mice. FACS
analyses of different activation markers revealed that levels of expression of MHCII, IL21R and
FAS were lower on B cells of BXSB.Yaa.Il6-/- than BXSB.Yaamice (Fig 5A). Interestingly, in
studies of spleens, the frequencies of total B220+IgM+ B cells were equivalent for BXSB.Yaa.
Il6-/-, BXSB.Yaa and BXSB.B6Ymice (Fig 5B, left panel and data not shown). In contrast, the
frequencies of splenic GC B cells and levels of FAS expression on B cells were significantly
lower for BXSB.Yaa.Il6-/- than BXSB.Yaa.Il6+/- mice (Fig 5B and S2 Fig). These data clearly
indicated that the effects of IL6 deficiency could be detected early in the life of BXSB.Yaamice,
consistent with an important role in disease initiation.
Earlier studies showed that BXSB.Yaamice have reduced frequencies of marginal zone B
cells [37] caused, at least in part, by high levels of IL21 expression [9]. We observed that in the
absence of IL6 signaling, the frequencies of marginal zone B cells were increased in BXSB.Yaa
Il6-/- compared with BXSB.Yaamice, though not significantly. However, the increased frequen-
cies of marginal zone B cells were not comparable to the frequencies seen with consomic BXSB.
B6Y controls suggesting that enhanced expression of IL6 in addition to IL21 contributes to the
reduction in the marginal zone B cell compartment of BXSB.Yaamice (S3A and S3B Fig).
Since activated monocytes and granulocytes are some of the other known disease manifesta-
tions of BXSB.Yaamice [38–40], we asked whether ablation of IL6 signaling had a significant
impact on these cell populations. We found that both CD11b+ and Gr-1+ cells had significantly
lower expression of MHCII in BXSB.Yaa.Il6-/- mice as compared to BXSB.Yaamice (S3C Fig)
suggesting that ablation of IL6 signaling reduced levels of activated monocytes and granulo-
cytes in BXSB.Yaamice.
Taken together, these data support our suggestion that interruption of IL6 signaling has a
significant impact on disease development from early in life that ultimately results in increased
survival of BXSB.Yaamice.
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Fig 4. IL6-deficient BXSB.Yaamice have reduced diseasemanifestations. (A) Sera from 6-month old
BXSB.Yaa.Il6-/-, BXSB.Yaa, BXSB.Il6-/-, BXSB, BXSB.B6Y and C57BL/6 mice were quantified for the
presence of ANA by ELISA (n = 3–10 mice per group). Each dot represents one mouse. Horizontal bars
indicate mean ± SEM and p values are calculated by one-way ANOVA with Tukey’s multiple comparison
tests. (B) Survival curve analysis of BXSB.Yaa.Il6+/- (n = 17), BXSB.Yaa.Il6-/—(n = 41) and archival data of
BXSB.Yaa (n = 93) mice. (C-E) IL6-competent and—deficient BXSB.Yaamice (n = 8–10) were compared for
disease manifestations including spleen weight (C), serum IgG1 and IgG2b (D) and serum anti-dsDNA
antibody titers (E). Bars represent mean ± SEM of observations from individual mice and p values are
calculated using two-way ANOVA. * p<0.05, ** p<0.01, ***p<0.0001.
doi:10.1371/journal.pone.0153059.g004
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IL6 acts upstream of IL21 in disease progression caused by Yaa
We previously reported that IL21, the signature cytokine secreted by CD4+ T follicular helper
(TFH) cells, is a critical determinant of the disease of BXSB.Yaamice [9–11]. Previous studies
reported that IL6 promotes the secretion of IL21 and that optimal TFH differentiation is medi-
ated by both IL6 and IL21 [15, 41]. In addition, our observation that BXSB.Yaamice have
expanded populations of TFH prompted us to examine whether ablation of IL6 would affect the
expansions of TFH cells. We found, first, that the frequencies of total CD4
+ T cells were signifi-
cantly reduced in spleens of IL6-deficient BXSB.Yaamice as compared to normal BXSB.Yaa
mice (Fig 6A, left panel, S4A Fig). Second, IL6 deficiency impacted the frequencies of TFH by 6
weeks of age as evidenced by the significant reduction in the frequencies of PD1+CD4+ T cells
in spleens of IL6-deficient BXSB.Yaamice (Fig 6A, right panel, S4B Fig) as compared to BXSB.
Yaamice or consomic BXSB.B6Y controls. To ascertain whether the reduction in CD4+ TFH
cell numbers required the autosomal SLE predisposition background of BXSB, we determined
the effects of an IL6 deficiency in B6.Yaamice, which develop a late onset autoimmune disease
due to Yaa. We found that B6.Yaa Il6-/- mice analyzed at 40 weeks of age had reduced frequen-
cies of CD4+ TFH cells (S5A and S5B Fig) as evidenced by the reduced expression of ICOS and
PD1 on CD4+ T cells of B6.YaaIl6-/- mice when compared with age matched WT controls (S5C
and S5D Fig). Finally, we quantified serum IL21 levels in IL6-deficient BXSB.Yaamice from 6
weeks to 5 months of age and found that the levels were significant decreased at both time
points (Fig 6B). This indicates that IL6 acts upstream of IL21 in the early phase of BXSB.Yaa
disease by limiting the development of TFH which are the primary source of IL21. From this we
concluded that IL6 acts to promote and maintain the development of TFH that are the primary
source of IL21 required for the SLE-like manifestations caused by the Yaamutation.
Discussion
IL6 is a pleiotropic proinflammatory cytokine that normally induces terminal differentiation of
B cells into plasma cells and memory B cells. IL6 also affects T cells by transcriptionally
Fig 5. Early activation of B cells in BXSB.Yaamice is reduced in the absence of IL6. 6–7.5 weeks old BXSB.Yaa (n = 5) and BXSB.Yaa.Il6-/- (n = 8) mice
were bled and (A) cells were stained with fluorescent-labeled antibodies to B220, IgM, MHCII, IL21R and FAS and analyzed by FACS. Expression of MHCII,
IL21R and FAS on viable single cells gated on B220+IgM+ is determined as MFI. (B) The frequencies of splenic total B cells (B220+IgM+) and GC B cells
(B220+IgM+PNAhiFAS+GL7+) were determined and expressed as percentages of total cells. Expression levels of FAS on GC B cells are depicted as mean
fluorescence intensity (MFI). Data are expressed as mean ± SEM of individual values obtained from each mouse and statistical analysis is done using two
tailed unpaired t test. * p<0.05, ** p<0.01, ***p<0.0001.
doi:10.1371/journal.pone.0153059.g005
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activating naïve CD4+ T cells to become TFH [42]. However, heightened expression of IL6 has
also been associated with a range of pathologies including a variety of autoimmune diseases in
humans and mice. A close association between expression of IL6 and progression of lupus-like
diseases has been described for several mouse models of SLE. Studies of autoimmune MRL.
Faslpr mice showed that serum levels of IL6 and the IL6 receptor (IL6R) increased in an age-
dependent manner [18–20]. Treatment with an IL6 neutralizing antibody led to reduced pro-
duction of autoantibodies in old (NZB x NZW)F1 mice [43]. In the pristane-induced model of
SLE, production of autoantibodies was abrogated in mice deficient in IL6 [44]. Conversely,
treatment of (NZB x NZW)F1 mice with IL6 accelerated disease progression [45]. Finally, sev-
eral studies of human SLE have suggested a prominent role for IL6 in B cell hyperactivity and
immunopathology in that elevated serum levels of IL6 were associated with disease activity or
levels of autoantibodies [21, 22]. It was also reported that B cells from patients with SLE spon-
taneously produced high levels of IL6 and expressed the IL6R [46, 47].
It is known that IL6 production by both human and murine B cells is enhanced following
cooperative signaling through TLR7 and CD40 [26]. Moreover, autoreactive B cells can be acti-
vated by simultaneous ligation of TLR7 and the BCR [48]. TLR7 recognizes ssRNA and signals
through MyD88 resulting in the activation of B cells in an NF-κB-dependent manner [49].
TLR7 is also considered to be an important contributor to the development of human lupus
[50–53]. The recombinant inbred mouse, BXSB.Yaa, develops an accelerated SLE-like disease
due to the translocation of a telomeric region of the X chromosome to the Y chromosome,
resulting in the duplication of at least 16 genes including Tlr7 in male mice [2, 3]. The duplica-
tion of Tlr7 has been shown to be primarily determinant responsible for the disease of BXSB.
Fig 6. IL6 deficiency reduces the TFH population in BXSB.Yaamice. (A) Splenocytes from BXSB.Yaa.Il6-/- (n = 8) BXSB.Yaa (n = 5), BXSB.B6Y (n = 6)
and C57BL/6J (n = 3) mice aged 6–9 weeks were stained with labeled antibodies to CD4, ICOS and PD1. Percentages of CD4+ T cells (CD4+) and TFH cells
(CD4+ICOShiPD1+) cells were determined by FACS and expressed as mean ± SEM. (B) Sera from BXSB.Yaa.Il6-/- (n = 12; 1.5–5 months old), BXSB.Il6-/-
(n = 5; 3–5 months old); BXSB.Yaa (n = 5; 3–5 months old) and BXSB (n = 5; 3–5 months old) mice were quantified for IL21 by sandwich ELISA. Data is
expressed as mean ± SEM from observations from each mouse. Statistical analysis was done using one-way ANOVA with Tukey’s multiple comparison test.
* p<0.05, ** p<0.01, ***p<0.0001.
doi:10.1371/journal.pone.0153059.g006
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Yaamice. Tlr7 is widely considered to be the genetic driver of overt SLE-like disease in the
presence of other lupus susceptibility alleles in mice and genome wide association studies iden-
tified TLR7 as a risk factor for SLE in humans [50–53].
The present study was designed to address the extent to which IL6 contributes to the auto-
immune disease caused by Yaa in BXSB mice and its cellular sources. We clearly established
that BXSB.Yaamice have elevated serum levels of IL6 in association with increasing disease
manifestations of hypergammaglobulinemia and levels of ANA in an age-dependent manner.
These findings are strongly supported by our results showing that IL6-deficient BXSB.Yaa
mice had greatly reduced levels of class-switched immunoglobulins and autoantibodies and
lived significantly longer. Further, Yaa causes B cells in these mice to become activated, highly
responsive to TLR7, BCR and TLR7 + BCR stimulation, and to secrete high levels of IL6, all of
which is consistent with B cells being the primary source of IL6 that promotes BXSB.Yaa dis-
ease. In addition, B cells also express type I interferon receptors (IFNAR). IFN1 has been
shown to sensitize B cells to be more responsive to BCR signals, enhance their proliferation
and survival and to augment antibody responses while promoting isotype switching [54–56].
Our results indicate that BXSB.Yaa B cells secrete large amounts of IL6 when stimulated simul-
taneously through IFNAR, TLR7 and the BCR suggesting that IL6 is critical to development of
disease at a very early stage.
Our previous studies established that IL21-IL21R signaling to B cells resulting in expanded
populations of CD4+ TFH is a critical factor in driving disease in these mice, while IL21-IL21R
signaling to CD8+ T and NK cells restricts disease progression [9–11]. Thus, the development
of TFH that secrete high levels of IL21 is a central component of the BXSB.Yaa disease. Here we
found that the frequency of CD4+ TFH cells and the serum levels of IL21 were significantly
decreased in IL6-deficient BXSB.Yaamice. Moreover, the involvement of IL6 in supporting the
expansion of TFH was evident in BXSB.Yaamice at early age mice. IL6 has been shown to be an
important factor in the activation of BCL6, which is the critical transcription factor in the dif-
ferentiation of naïve CD4+ T cells to TFH [14, 15]. IL6 has been shown to support TFH differen-
tiation even at their earliest stages of lineage commitment [42, 57, 58]. The abundance of IL6
secreted mainly by activated B cells in a TLR7-dependent manner suggests that they are the
major source of IL6 that drives the expansion of IL21-producing TFH in BXSB.Yaamice.
Taken together, the results of this study define an important role for IL6 in the development
and progression of the SLE-like disease of BXSB.Yaamice, suggesting that IL6 signaling could
provide an important point for therapeutic intervention. A human open-label phase I trial in
SLE patients of Tocilizumab, a monoclonal antibody that inhibits binding of IL6 to its receptor,
revealed improvements in disease activity and reduced levels of serum autoantibodies [59].
However, the patients also experienced an increased number of infections suggesting that
changes in the protocol or adoption of new approaches to blocking IL6 signaling were in order.
In another double blind phase II trial, SLE patients treated intravenously with Sirukumab, a
fully human anti-IL6 monoclonal antibody, suffered from some minor respiratory infections
[60]. If direct interference with IL6-IL6R signaling is not possible due to adverse effects, several
JAK inhibitors such as Tofacitinib and Ruxolitinib that prevent downstream signaling from the
IL6R may be worth investigating for therapeutic purposes. Since IL6 production is enhanced
by co-stimulation through TLR7 and the BCR, other therapeutic interventions could include
inhibitors of TLR7, IRF7 and STAT activity.
Supporting Information
S1 Fig. Concomitant signaling through TLR, BCR and type I interferon enhances IL6 secre-
tion by BXSB.Yaa B cells. Purified B cells from BXSB.Yaa and BXSB mice were cultured in
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the presence or absence of R837 (50ng/ml); anti-BCR antibody (2g/ml); IFN and (40U/ml),
either alone or in combinations, for 24h. Supernatants were collected and quantified for IL6
levels by standard sandwich ELISA method. Data is expressed as mean ± SEM of triplicate
wells and is representative of two independent experiments.
(TIF)
S2 Fig. Gating strategy for germinal center B cells. Splenocytes from BXSB.Yaa, BXSB.Yaa
and BXSB mice were isolated and stained with anti-mouse antibodies to identify germinal cen-
ter B cells (B220+GL7+Fas+).
(TIF)
S3 Fig. Abrogating IL6 signaling diminishes marginal zone B cell frequencies and activa-
tion of monocytes. Splenocytes from BXSB.Yaa.Il6-/-, BXSB.Yaa and consomic BXSB.B6Y
mice were isolated and stained with anti-mouse antibodies to determine (A-B) marginal zone
B cells (CD19+IgM+B220+CD5-CD23-CD21+) and (B) MHCII expression on CD11b+ and Gr-
1+ cells.
(TIF)
S4 Fig. Gating strategy for CD4 TFH cells. Splenocytes from B6.Yaa.Il6
-/- and B6.Yaa Il6+/-
mice were isolated and stained with anti-mouse antibodies to determine (A) CD4TFH cells
(PD1+ ICOShi CD4+) and (B) PD1+ CD4+ cells.
(TIF)
S5 Fig. IL6 acts upstream of IL21 in the disease progression of BXSB.Yaamice. Splenocytes
from B6.Yaa.Il6-/- and B6.Yaa Il6+/- mice were isolated and stained with anti-mouse antibodies.
(A) FACS plots determine ICOS vs PD-1 expression on CD4+ T cells. Numbers in the plots
represent percentage of total cells. Bar diagrams represent (B) percentages of CD4+ T cells (C)
percentages of CD4TFH (PD1
+ ICOS+ CD4+) cells (D) ICOS and PD-1 expression (MFI) on
CD4 T cells. (B) and (C) represent frequencies of parent population. Data is mean ± SEM of
7–8 mice per group. P values were determined by two way ANOVA.
(TIF)
S1 Table. List of Antibodies used in FACS and ELISA.
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